You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明生物(02269.HK)拟收购苏桥生物逾90%股权
阿思达克 03-18 11:50
药明生物(02269.HK)宣布,与康桥资本及聚明创投等达成收购协议,将收购合同定制研发生产企业(CDMO)苏桥生物超过90%的股份,预计交易将在今年第二季度完成。

苏桥生物主要提供细胞株开发、工艺开发以及临床GMP生产等服务,拥有超过250名员工,收购完成後,药明生物将新增生物药原液二十一厂(MFG21,总计7,000升)和制剂十一厂(DP11,液体和冻乾)。

公司并与康桥资本建立战略合作,未来将赋能康桥资本被投企业发现、开发和生产生物药。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account